Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epidiolex in adult drug-resistant epilepsy
NCT02700412Phase 1Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Apr 2015
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cannabidiol in epilepsy, sponsored by University of Alabama at Birmingham. Primary endpoints: Number of Participants With Severe Adverse Events at 1 year, Number of Participants With Change in Resting Blood Pressure or Heart Rate at 1 year and 1 more. Started Apr 2015; status: completed.
02
Drugs
cannabidiol
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02700412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02700412.